Paper Details

  1. Home
  2. Paper Details

Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.

Author: GudesblattMark, KapadiaShivani, LyonsJennifer, RomanCortnee, SchmidtHollie, ShankarSai L, SingerBarry A, ThomasJessica

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This concept elicitation study aimed to identify treatment-related concepts most meaningful to patients taking diroximel fumarate (DRF) for relapsing multiple sclerosis (MS). The study found that patients highly valued DRF's improved gastrointestinal tolerability and low treatment discontinuation rates compared to dimethyl fumarate (DMF). These findings highlight the importance of considering patient perspectives on treatment-related concepts when evaluating drug efficacy and adherence.
Paper Details　
Original Abstract of the Article :
Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis (MS). Clinical and real-world studies of DRF have demonstrated improved gastrointestinal (GI) tolerability and low (< 1%) GI-related treatment discontinuation versus dimethyl fumarate (DMF) and high rates of treatment adhe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098785/

データ提供：米国国立医学図書館（NLM）

Diroximel Fumarate: A New Era of Gastrointestinal Tolerability for MS Patients

This study delves into the realm of [multiple sclerosis (MS) treatment] and investigates the [health-related quality of life] associated with [diroximel fumarate (DRF)], a novel oral fumarate medication. The researchers conducted a [concept elicitation study] involving patient interviews to understand the [treatment-related concepts] that are most meaningful to patients and how these concepts shape their perspectives on DRF.

Improving Patient Experience and Adherence

This research is particularly significant for [individuals with relapsing MS] who may have struggled with the gastrointestinal side effects of [dimethyl fumarate (DMF)]. The study's findings suggest that [DRF offers improved gastrointestinal tolerability] compared to DMF, potentially leading to [higher rates of treatment adherence] and a better overall patient experience. This is akin to discovering a smoother and more comfortable path through a rugged desert, allowing travelers to navigate with greater ease and fewer obstacles.

Quality of Life and Treatment Adherence

The importance of [gastrointestinal tolerability] in the context of MS treatment cannot be overstated. These side effects can significantly impact a patient's [quality of life and adherence to treatment]. By offering a [more tolerable option], DRF could potentially lead to [better symptom control, improved functional ability, and a greater sense of well-being] for individuals with MS.

Dr. Camel's Conclusion

This study, like a cool spring in a desert landscape, offers a refreshing perspective on MS treatment. By emphasizing the importance of gastrointestinal tolerability, the research highlights the need for medications that improve patient experience and enhance adherence. DRF, like a beacon of hope in the desert of MS research, provides a new avenue for improving the lives of individuals struggling with this challenging disease.
Date :
  1. Date Completed 2022-06-30
  2. Date Revised 2022-12-13
Further Info :

Pubmed ID

35556227

DOI: Digital Object Identifier

PMC9098785

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.